Arura Pharma Inc. announces completion of the acquisition of the Neolia Brands for USD$6,800,000
Change to its Board of directors and trading resumption
Arura Pharma Inc. announced that it has completed the acquisition of the Neolia(TM) Brands for an aggregate purchase price of $USD6,800,000. Arura has entered into definitive asset purchase agreements dated as of August 1, 2007 with Primolio Sales Inc. and Valco Enterprises LLC to acquire the world-wide rights to the Neolia(TM) Brands family of trademarks. The assets purchased by Arura also include all intellectual property, customers' and suppliers' lists, outstanding and future purchase orders made in relation to the Neolia(TM) Brands.
As part of this transaction, Mr. Rudy Huber accepted to resign from the Board of Directors of Arura so that Mr. Claus Brueckner be immediately appointed as a director of Arura. Mr. Brueckner was awarded a bachelor of arts degree in 1982 and a Master of Business Administration degree in 1983. Upon completion of his studies, Mr. Brueckner held various positions in sales and marketing with General Mills, Cargill and Schwan's. In 1995, Mr. Brueckner and his partners formed several companies, collectively referred to as the AXIOM Group of Companies, to market branded food products to membership warehouse clubs and supermarkets. Mr. Brueckner purchased his partners' interest in the AXIOM Group of Companies in 2001. Today, the AXIOM Group of Companies sells primarily branded products in North America, Asia and Europe.
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
BASF Fine Chemicals Switzerland SA and BASF Orgamol Pharma Solutions SA merger announced - Company renamed BASF Pharma (Evionnaz) SA

TRON -Translationale Onkologie an der Universitätsmedizin der JGU Mainz gemeinnützige GmbH - Mainz, Germany
